TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Industry News Articles > How to achieve inspection readiness

How to achieve inspection readiness

Authors: Anne Marie Gaffney & Kate Coleman

Are you concerned about your upcoming Regulatory Inspection? How do you prepare for it and prepare your Subject Matter Experts (SMEs)? Is your Inspection Readiness Plan in place?

inspection readinessThe development of a detailed Inspection Readiness Plan will reduce your concerns and help you work towards a successful Inspection outcome.

Your Inspection Readiness Plan should involve a cross-functional team of the appropriate level of personnel in your organization. This team is key to ensuring the site is prepared for the Inspection and ensuring identified actions are completed in advance of the Inspector arriving on site. The Plan should include details of the logistics of the Inspection i.e. what room it will take place in, where the war room or back-up room will be located, who the scribe will be etc.  Other items to consider in the lead-up to the Inspection are your SOP for handling inspections, identifying and preparing the SMEs, and identifying the main areas of weakness in order to practice delivery of the site position.

 

Review your Handling of External Inspections SOP.  It should include:

  • Details relating to notification of an inspection to the site team (for announced inspections) once received from the Health Authority.
  • For an unannounced inspection, a mechanism for notification of the Inspector’s presence on site.
  • Details on how document flow will be managed e.g. communication of a request to the wider team, review of a document prior to submission to the Inspector and control of original and any copied documents, if provided, to the Inspector.
  • Details on how the record of the Inspection should be maintained; this should include the documentation and version number provided to the Inspector, details of any documentation taken off site by the Inspector, daily scribe notes, list of personnel met and the opening and closing meeting minutes.

Identification and Preparation of Subject Matter Experts.

Remember that the most technical person may not be the best person to place in front of an Inspector. FDA Inspectors are trained to interrogate and investigate and draw conclusions from what they are told. They are technically competent in their area of inspection and are particularly strong in interrogating and eliciting information. Therefore, select your SME carefully. It is key that you understand the FDA interrogation techniques and simulate inspection interviews in preparation.

Ensure the SMEs understand the different questioning techniques used. Closed-ended questions will elicit a Yes/No answer e.g. Was a deviation raised for this? Open-ended questions on the other hand can elicit a lot of information e.g. “Tell me about this deviation.”  A leading question could be  “Do you believe this deviation was handled appropriately?”. The inspector could make an assumptive question e.g. “Is a deviation not required to be raised for minor non-conformances?” where they are making an assumption in asking the question.

The SMEs should always answer with a fact-based response, never an opinion! A system overview in a policy or procedure maybe used during the Inspection response to help support the response. Remember, responses are never off the record i.e. during lunch time or towards the end of the week when the Inspector appears more casual or relaxed. The SME must remember this is an official inspection at all times. Answer the specific question and stop speaking! This maybe hard, particularly if there is a silence.  The SME should never feel they have to fill that silence! Listen to the question properly and reword the question to confirm your accurate understanding of the question. And….Always tell the truth. Training sessions should be carried out to simulate an inspection setting and ensuring your SME is prepared appropriately.

Identify your areas of weakness in advance so they can be corrected or prepared.

If an issue can’t be eliminated in its entirety, prepare how the Company shall discuss the issue in a way that clearly represents how the issue was identified and how it was, or is being addressed. What are the major deviations that occurred since the last inspection? Are you satisfied with the manner in which they were closed? Were the CAPAs appropriate and effective? Have you assessed your CAPA effectiveness? What risk assessments have been completed? Are you comfortable defending your risk approach? Where there are action plans still in place, can you show the timeline of actions and progress to date using the appropriate quality system?

 

Related posts
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Virtual Audits: To be, or not to be, that is the question
Virtual Audits: To be, or not to be, that is the question
26th January 2022
Quality Risk Management ICH Q9 – Revision published for public comments
Quality Risk Management ICH Q9 – Revision published for public comments
5th January 2022
Search
Upcoming Events

September 28 - May 29th, 2022

NLS DAYS 2022

Visit us at booth X51

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
6h

At PharmaLex, one of our core values is expanding our global community. In March, we welcomed Japan, East Asia, and Southeast Asia into our global pharmaceutical #productdevelopment as a result of a merger agreement with Ascent Development Services.
https://lnkd.in/eGFf_AKv

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Thanks so much for your support over the past 30 days. Your commitment and timely communication have made working with you all a pleasant experience.

    US Biotech
    Senior QA Associate
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for